RESUMEN
Proprotein convertase subtilisin/kexin 9 (PCSK9) inhibitors have been shown to regulate lipid metabolism and reduce the risk of cardiovascular events. This study explores the effect and potential mechanism of PCSK9 inhibitors on lipid metabolism and coronary atherosclerosis. HepG2 cells were incubated with PCSK9 inhibitor. ApoE-/- mice were fed with a high fat to construct an atherosclerosis model, and then treated with PCSK9 inhibitor (8 mg/kg for 8 w). PCSK9 inhibitor downregulated microRNA (miRNA)-130a-3p expression in a dose-dependent manner. And, miR-130a-3p could bind directly to the 3' untranslated region (3'-UTR) region of LDLR to down-regulate LDLR expression in HepG2 cells, as confirmed by the luciferase reporter gene assay. In addition, miR-130a-3p overexpression significantly attenuated the promoting effect of PCSK9 inhibitor on LDLR and DiI-LDL uptake in HepG2 cells. More importantly, in vivo experiments confirmed that PCSK9 inhibitor could significantly inhibit miR-130a-3p levels and promote LDLR expression in liver tissues, thus regulating serum lipid profile and alleviating the progression of coronary atherosclerosis. PCSK9 inhibitor could moderately improve coronary atherosclerosis by regulating miR-130a-3p/LDLR axis, providing an exploitable strategy for the treatment of coronary atherosclerosis.
Asunto(s)
Aterosclerosis , Enfermedad de la Arteria Coronaria , MicroARNs , Ratones , Animales , Humanos , Proproteína Convertasa 9/genética , Proproteína Convertasa 9/metabolismo , Proproteína Convertasa 9/farmacología , Subtilisina/metabolismo , Subtilisina/farmacología , Receptores de LDL/genética , Receptores de LDL/metabolismo , Ratones Noqueados para ApoE , Proproteína Convertasas/genética , Proproteína Convertasas/metabolismo , Proproteína Convertasas/farmacología , Aterosclerosis/tratamiento farmacológico , Aterosclerosis/genética , Aterosclerosis/metabolismo , Hepatocitos , Células Hep G2 , MicroARNs/genética , MicroARNs/metabolismoRESUMEN
Lactiplantibacillus plantarum and Saccharomyces cerevisiae are frequently co-isolated in food, although playing different roles. This study aimed at investigating the microbial interaction between L. plantarum and S. cerevisiae, especially cell-cell direct interaction and their mechanism. Cell-cell and supernatant-cell coculture models were set up, with CFU counting, OD600 measurement, optical and atomic force microscopy performed to examine the growth and morphology of L. plantarum and S. cerevisiae cells. In cell-cell coculture model, L. plantarum cells inhibited S. cerevisiae growth (inhibition rate ~80%) with its own growth pattern unaffected. Cell-cell aggregation happened during coculture with surface roughness changed and partial S. cerevisiae cell lysis. Mature (24 h) L. plantarum cell-free culture supernatant showed inhibition (35%-75%) on S. cerevisiae growth independent of pH level, while supernatant from L. plantarum-S. cerevisiae coculture showed relatively stronger inhibition. Upon transcriptomics analysis, hypothesis on the mechanism of microbial interaction between L. plantarum and S. cerevisiae was demonstrated. When L. plantarum cell density reached threshold at 24 h, all genes in lamBDCA quorum sensing (QS) system was upregulated to potentially increase adhesion capability, leading to the aggregation to S. cerevisiae cell. The downregulation of whole basic physiological activity from DNA to RNA to protein, cell cycle, meiosis, and mitogen-activated protein kinase (MAPK) signaling pathways, as well as growth maintenance essential genes ari1, skg6, and kex2/gas1 might induce the decreased growth and proliferation rate and partial death of S. cerevisiae cells in coculture. IMPORTANCE L. plantarum and S. cerevisiae are frequently co-isolated in food, although playing different roles. The co-existence of L. plantarum and S. cerevisiae could result in variable effects, raising economic benefits and safety concerns in food industry. Previous research has reported the microbial interaction between L. plantarum and S. cerevisiae mainly rely on the signaling through extracellular metabolites. However, cell-cell aggregation has been observed with mechanism remain unknown. In the current study, the microbial interaction between L. plantarum and S. cerevisiae was investigated with emphasis on cell-cell direct interaction and further in-depth transcriptome level study showed the key role of lamBDCA quorum sensing system in L. plantarum. The results yield from this study demonstrated the antagonistic effect between L. plantarum and S. cerevisiae.
Asunto(s)
Lactobacillus plantarum , Proteínas de Saccharomyces cerevisiae , Saccharomyces cerevisiae , Lactobacillus plantarum/genética , Lactobacillus plantarum/metabolismo , Transcriptoma , Interacciones Microbianas , ARN/metabolismo , ARN/farmacología , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Proteínas de Saccharomyces cerevisiae/genética , Proteínas de Saccharomyces cerevisiae/metabolismo , Proteínas de Saccharomyces cerevisiae/farmacología , Proproteína Convertasas/genética , Proproteína Convertasas/metabolismo , Proproteína Convertasas/farmacologíaRESUMEN
OBJECTIVES: The aim of the study was to compare the effects of atorvastatin, a proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i), and 17ß-estradiol on oxidative muscle mitochondria in a model of menopause with obesity. METHODS: Female Wistar rats consumed either a standard diet (nâ=â12) or a high-fat/calorie diet (HFCD: nâ=â60). At week 13, standard diet-fed rats underwent a sham operation, whereas HFCD-fed rats underwent either a sham operation (nâ=â12) or an ovariectomy (nâ=â48). At week 19, all sham-operated rats received vehicle, and ovariectomized HFCD-fed rats received either vehicle, 40âmg/kg/d of atorvastatin, 4âmg/kg/d of PCSK9i (SBC-115076), or 50âµg/kg/d of 17ß-estradiol for 3 weeks (nâ=â12/group). Metabolic parameters and soleus muscle physiology were investigated at the end of week 21. RESULTS: Sham-operated and ovariectomized HFCD-fed rats developed obesity, hyperlipidemia, and insulin resistance, also showing increased oxidative phosphorylation (OXPHOS) proteins, ratio of p-Drp1-to-total Drp1 protein, malondialdehyde level, mitochondrial reactive oxygen species, and mitochondrial membrane depolarization in soleus muscle. All drugs equally decreased insulin resistance, OXPHOS proteins, ratio of p-Drp1-to-total Drp1 protein, and malondialdehyde level in soleus muscle. Only atorvastatin and PCSK9i attenuated hypertriglyceridemia, whereas 17ß-estradiol had greater efficacy in preventing weight gain than the other two drugs. In addition, 17ß-estradiol decreased mitochondrial reactive oxygen species and mitochondrial membrane depolarization. Atorvastatin increased ratio of cleaved caspase 3,8-to-procaspase 3,8, and cytochrome C. CONCLUSIONS: 17ß-Estradiol exhibits the greatest efficacy on the attenuation of obesity with the least harmful effect on skeletal muscle in a model of menopause with obesity, yet its effect on the treatment of hyperlipidemia is inferior to those of standard lipid-lowering agents.
Asunto(s)
Inhibidores de Hidroximetilglutaril-CoA Reductasas , Resistencia a la Insulina , Animales , Estrógenos/farmacología , Femenino , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Mitocondrias , Obesidad/tratamiento farmacológico , Ovariectomía , Estrés Oxidativo , Proproteína Convertasas/farmacología , Ratas , Ratas Wistar , Subtilisinas/farmacologíaRESUMEN
BACKGROUND Previous studies of human and animal models indicate that inflammation alters lipid metabolism. The pro-protein convertase subtilisin kexin type 9 (PCSK9) plays an important role in lipid metabolism. MATERIAL AND METHODS We examined the effect of inflammation on PCSK9 expression and lipid deposition in the kidneys of mice with Adriamycin-induced nephropathy. RESULTS The results indicated an increased expression of inflammatory cytokines and lipid deposition over 12 weeks. During this time, the expression of PCSK9 and its transcriptional activator (hepatocyte nuclear factor 1alpha, HNF1alpha) decreased, and the expression of the low-density lipoprotein receptor (LDLR) and its transcriptional activator (sterol regulatory element binding protein-2, SREBP-2) increased. Exogenous inflammation appeared to further aggravate this process. CONCLUSIONS Our mouse model of nephropathy suggests that a key step in the inflammation-induced deposition of lipids in the kidneys is the downregulation renal PCSK9 expression.
Asunto(s)
Doxorrubicina/toxicidad , Metabolismo de los Lípidos/efectos de los fármacos , Síndrome Nefrótico/inducido químicamente , Síndrome Nefrótico/metabolismo , Proproteína Convertasa 9/metabolismo , Animales , Modelos Animales de Enfermedad , Regulación hacia Abajo/efectos de los fármacos , Doxorrubicina/farmacología , Factor Nuclear 1-alfa del Hepatocito/metabolismo , Inflamación/metabolismo , Riñón/metabolismo , Enfermedades Renales , Lípidos/fisiología , Lipoproteínas LDL/metabolismo , Masculino , Ratones , Ratones Endogámicos BALB C , Nefritis/inducido químicamente , Nefritis/metabolismo , Proproteína Convertasa 9/biosíntesis , Proproteína Convertasas/metabolismo , Proproteína Convertasas/farmacología , Receptores de LDL/genética , Receptores de LDL/metabolismo , Proteína 2 de Unión a Elementos Reguladores de Esteroles/metabolismoRESUMEN
Cartilage loss in osteoarthritis (OA) results from altered local production of growth factors and metalloproteases (MMPs). Furin, an enzyme involved in the protein maturation of MMPs, might regulate chondrocyte function. Here, we tested the effect of furin on chondrocyte catabolism and the development of OA. In primary chondrocytes, furin reduced the expression of MMP-13, which was reversed by treatment with the furin inhibitor α1-PDX. Furin also promoted the activation of Smad3 signaling, whereas activin receptor-like kinase 5 (ALK5) knockdown mitigated the effects of furin on MMP-13 expression. Mice underwent destabilization of the medial meniscus (DMM) to induce OA, then received furin (1 U/mice), α1-PDX (14 µg/mice) or vehicle. In mice with DMM, the OA score was lower with furin than vehicle treatment (6.42 ± 0.75 vs 9.16 ± 0.6, p < 0.01), and the number of MMP-13(+) chondrocytes was lower (4.96 ± 0.60% vs 20.96 ± 8.49%, p < 0.05). Moreover, furin prevented the increase in ALK1/ALK5 ratio in cartilage induced by OA. Conversely, α1-PDX had no effect on OA cartilage structure. These results support a protective role for furin in OA by maintaining ALK5 receptor levels and reducing MMP-13 expression. Therefore, furin might be a potential target mediating the development of OA.
Asunto(s)
Furina/farmacología , Metaloproteinasa 13 de la Matriz/efectos de los fármacos , Osteoartritis/prevención & control , Factor de Crecimiento Transformador beta/farmacología , Receptores de Activinas Tipo I/análisis , Receptores de Activinas Tipo I/efectos de los fármacos , Receptores de Activinas Tipo II , Animales , Condrocitos/efectos de los fármacos , Condrocitos/metabolismo , Ratones , Osteoartritis/tratamiento farmacológico , Proproteína Convertasas/farmacología , Receptor Tipo I de Factor de Crecimiento Transformador beta/efectos de los fármacosRESUMEN
Microbial cell walls contain pathogenic lipids, including LPS in gram-negative bacteria, lipoteichoic acid in gram-positive bacteria, and phospholipomannan in fungi. These pathogen lipids are major ligands for innate immune receptors and figure prominently in triggering the septic inflammatory response. Alternatively, pathogen lipids can be cleared and inactivated, thus limiting the inflammatory response. Accordingly, biological mechanisms for sequestering and clearing pathogen lipids from the circulation have evolved. Pathogen lipids released into the circulation are initially bound by transfer proteins, notably LPS binding protein and phospholipid transfer protein, and incorporated into high-density lipoprotein particles. Next, LPS binding protein, phospholipid transfer protein, and other transfer proteins transfer these lipids to ApoB-containing lipoproteins, including low-density (LDL) and very-low-density lipoproteins and chylomicrons. Pathogen lipids within these lipoproteins and their remnants are then cleared from the circulation by the liver. Hepatic clearance involves the LDL receptor (LDLR) and possibly other receptors. Once absorbed by the liver, these lipids are then excreted in the bile. Recent evidence suggests pathogen lipid clearance can be modulated. Importantly, reduced proprotein convertase subtilisin/kexin type 9 activity increases recycling of the LDLR and thereby increases LDLR on the surface of hepatocytes, which increases clearance by the liver of pathogen lipids transported in LDL. Increased pathogen lipid clearance, which can be achieved by inhibiting proprotein convertase subtilisin/kexin type 9, may decrease the systemic inflammatory response to sepsis and improve clinical outcomes.
Asunto(s)
Lípidos/sangre , Hígado/metabolismo , Proproteína Convertasas/sangre , Sepsis/sangre , Subtilisinas/sangre , Animales , Humanos , Lipoproteínas HDL/sangre , Ratones , Proproteína Convertasas/farmacología , Receptores de LDL/sangre , Proteínas de Saccharomyces cerevisiae/sangre , Proteínas de Saccharomyces cerevisiae/farmacología , Subtilisinas/farmacologíaAsunto(s)
Aterosclerosis/terapia , Proteínas Relacionadas con Receptor de LDL/metabolismo , Proproteína Convertasas/metabolismo , Proproteína Convertasas/uso terapéutico , Serina Endopeptidasas/metabolismo , Serina Endopeptidasas/uso terapéutico , LDL-Colesterol/metabolismo , Humanos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Polimorfismo Genético , Proproteína Convertasa 9 , Proproteína Convertasas/farmacología , Factores de Riesgo , Serina Endopeptidasas/farmacologíaAsunto(s)
Humanos , Aterosclerosis/terapia , Proteínas Relacionadas con Receptor de LDL/metabolismo , Proproteína Convertasas/metabolismo , Proproteína Convertasas/uso terapéutico , Serina Endopeptidasas/metabolismo , Serina Endopeptidasas/uso terapéutico , LDL-Colesterol/metabolismo , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Polimorfismo Genético , Proproteína Convertasas/farmacología , Factores de Riesgo , Serina Endopeptidasas/farmacologíaRESUMEN
Proprotein convertase substilisin/kexin type 9 (PCSK9) promotes the degradation of low-density lipoprotein (LDL) receptor (LDLR) and thereby increases serum LDL-cholesterol (LDL-C). We have developed a humanized monoclonal antibody that recognizes the LDLR binding domain of PCSK9. This antibody, J16, and its precursor mouse antibody, J10, potently inhibit PCSK9 binding to the LDLR extracellular domain and PCSK9-mediated down-regulation of LDLR in vitro. In vivo, J10 effectively reduces serum cholesterol in C57BL/6 mice fed normal chow. J16 reduces LDL-C in healthy and diet-induced hypercholesterolemic cynomologous monkeys, but does not significantly affect high-density lipoprotein-cholesterol. Furthermore, J16 greatly lowered LDL-C in hypercholesterolemic monkeys treated with the HMG-CoA reductase inhibitor simvastatin. Our data demonstrate that anti-PCSK9 antibody is a promising LDL-C-lowering agent that is both efficacious and potentially additive to current therapies.
Asunto(s)
Anticuerpos Monoclonales Humanizados/farmacología , LDL-Colesterol/efectos de los fármacos , Inhibidores de Hidroximetilglutaril-CoA Reductasas/uso terapéutico , Primates , Proproteína Convertasas/antagonistas & inhibidores , Animales , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales Humanizados/inmunología , Anticuerpos Monoclonales Humanizados/uso terapéutico , Dominio Catalítico/inmunología , Línea Celular Tumoral , Colesterol/sangre , Colesterol en la Dieta/administración & dosificación , Colesterol en la Dieta/farmacología , HDL-Colesterol/sangre , HDL-Colesterol/efectos de los fármacos , LDL-Colesterol/sangre , Grasas de la Dieta/administración & dosificación , Grasas de la Dieta/farmacología , Relación Dosis-Respuesta a Droga , Quimioterapia Combinada/métodos , Epítopos/inmunología , Femenino , Fluorobencenos/farmacología , Fluorobencenos/uso terapéutico , Inhibidores de Hidroximetilglutaril-CoA Reductasas/farmacología , Hipercolesterolemia/sangre , Hipercolesterolemia/inducido químicamente , Hipercolesterolemia/tratamiento farmacológico , Hígado/efectos de los fármacos , Hígado/metabolismo , Macaca fascicularis , Masculino , Ratones , Ratones Endogámicos C57BL , Ratones Noqueados , Modelos Moleculares , Proproteína Convertasa 9 , Proproteína Convertasas/inmunología , Proproteína Convertasas/farmacología , Pirimidinas/farmacología , Pirimidinas/uso terapéutico , Receptores de LDL/metabolismo , Rosuvastatina Cálcica , Serina Endopeptidasas/sangre , Serina Endopeptidasas/inmunología , Serina Endopeptidasas/farmacología , Simvastatina/farmacología , Simvastatina/uso terapéutico , Sulfonamidas/farmacología , Sulfonamidas/uso terapéuticoRESUMEN
The fate of pluripotent cells in early mouse embryos is controlled by graded Nodal signals that are activated by the endoproteases Furin and Pace4. Soluble forms of Furin and Pace4 cleave proNodal in vitro and after secretion in transfected cells, but direct evidence for paracrine activity in vivo is elusive. Here, we show that Furin and Pace4 are released by the extraembryonic microenvironment, and that they cleave a membrane-bound reporter substrate in adjacent epiblast cells and activate Nodal to maintain pluripotency. Secreted Pace4 and Furin also stimulated mesoderm formation, whereas endoderm was only induced by Pace4, correlating with a difference in the spatiotemporal distribution of these proteolytic activities. Our analysis of paracrine Furin and Pace4 activities and their in vivo functions significantly advances our understanding of how the epiblast is patterned by its microenvironment. Adding cell-cell communication to the pleiotropic portfolio of these proteases provides a new framework to study proprotein processing also in other relevant contexts.
Asunto(s)
Furina/metabolismo , Estratos Germinativos/enzimología , Comunicación Paracrina , Células Madre Pluripotentes/metabolismo , Proproteína Convertasas/metabolismo , Animales , Ectodermo/embriología , Endodermo/efectos de los fármacos , Endodermo/embriología , Membranas Extraembrionarias/enzimología , Furina/farmacología , Regulación del Desarrollo de la Expresión Génica/efectos de los fármacos , Mesodermo/efectos de los fármacos , Mesodermo/embriología , Ratones , Proteína Nodal/metabolismo , Proproteína Convertasas/farmacología , Transducción de Señal/fisiologíaRESUMEN
The proprotein convertases (PCs) are serine proteases involved in various physiological processes and their overactivity or inactivity has been linked to different disorders. PCs are responsible for the proteolytic processing of various polypeptide precursors. Here, we discuss the effect of their N-terminal prosegments on various PC substrates processing and functions.
Asunto(s)
Proproteína Convertasas/farmacología , Secuencia de Aminoácidos , Fragmentos de Péptidos/farmacología , Proproteína Convertasas/química , Estructura Terciaria de ProteínaRESUMEN
Sterol regulatory element-binding proteins (SREBPs) are transcription factors governing transcription of genes related to cholesterol and fatty acid metabolism. To become active, SREBPs must undergo a proteolytic cleavage to allow an active NH(2)-terminal segment to translocate into the nucleus. SKI-1/S1P is the first protease in the proteolytic activation cascade of SREBPs. SREBP inhibition may be useful, for example, in the treatment of liver steatosis caused by homocysteine-induced lipid synthesis. Accordingly, we overexpressed inhibitory prodomains (proSKI) of SKI-1/S1P in HepG2 cells to block SREBP activation to evaluate the potential of SKI-1/S1P in controlling cellular cholesterol synthesis. SKI-1/S1P inhibition resulted in reduced cholesterol synthesis and mRNA levels of the rate-limiting enzymes, HMG-CoA reductase and squalene epoxidase, in the cholesterol synthetic pathway. The inhibitory effect was maintained in the presence of homocysteine-induced endoplasmic reticulum stress. A gene set enrichment analysis was performed to elucidate other metabolic effects caused by SKI-1/S1P inhibition. SKI-1/S1P inhibition was observed to affect a number of other metabolic pathways, including glycolysis and citric acid cycle. These results demonstrate that inhibition of SREBPs decreases cholesterol synthesis in HepG2 cells both in the absence and presence of homocysteine. SKI-1/S1P inhibition may cause widespread changes in other key metabolic pathways.
Asunto(s)
Colesterol/metabolismo , Homocisteína/metabolismo , Proproteína Convertasas/antagonistas & inhibidores , Proteínas de Unión a los Elementos Reguladores de Esteroles/antagonistas & inhibidores , Línea Celular , Glucólisis , Humanos , Redes y Vías Metabólicas , Análisis de Secuencia por Matrices de Oligonucleótidos , Proproteína Convertasas/farmacología , ARN Mensajero/metabolismo , Serina EndopeptidasasRESUMEN
In some species, such as songbirds, much is known about how the brain regulates vocal learning, production, and perception. What remains a mystery is what regulates the motivation to communicate. European starlings (Sturnus vulgaris) sing throughout most of the year, but the social and environmental factors that motivate singing behavior differ seasonally. Male song is highly sexually motivated during, but not outside of, the breeding season. Brain areas outside the song control system, such as the medial preoptic nucleus (POM) and ventral tegmental area (VTA), have been implicated in regulating sexually motivated behaviors in birds, including song. The present study was designed to explore whether these regions, as well as three song control nuclei [area X, the high vocal center (HVC), and the robust nucleus of the arcopallium (RA)], might be involved differentially in song produced within compared to outside of a breeding context. We recorded the behavioral responses of breeding and nonbreeding condition male starlings to the introduction of a female conspecific. Males did not show context-dependent differences in the overall amount of song sung. However, immunocytochemistry for the protein product of the immediate early gene cFOS revealed a positive linear relationship between the total amount of songs sung and number of cFOS-labeled cells in POM, VTA, HVC, and RA for birds singing during, but not outside of, a breeding context. These results suggest that these regions differentially regulate male song production depending on reproductive context. Overall the data support the hypothesis that the POM and VTA interact with the song control system, specifically HVC and RA, to regulate sexually motivated vocal communication in songbirds.
Asunto(s)
Encéfalo/metabolismo , Regulación de la Expresión Génica/fisiología , Motivación , Proteínas Proto-Oncogénicas c-fos/metabolismo , Conducta Sexual Animal/fisiología , Vocalización Animal/fisiología , Análisis de Varianza , Animales , Conducta Animal , Western Blotting/métodos , Encéfalo/citología , Recuento de Células/métodos , Femenino , Inmunohistoquímica/métodos , Masculino , Proproteína Convertasas/farmacología , EstorninosRESUMEN
Processing of prohormones to generate active products typically occurs at basic residues via cleavage by proprotein convertases. A less common type of cleavage is mediated at hydrophobic (L, V, F, N) or small amino acid (A, T, S) residues. Efforts to identify the proteinases responsible for processing precursors at their hydrophobic amino acids has led to the recent cloning of a new type-1 membrane-bound subtilase called SKI-1. The NH2-terminal region of prosomatostatin, previously shown to contain a sorting signal for the regulated secretory pathways, is processed to generate PSST[1-10]. The exact cleavage mechanism is unknown, but has been assumed to involve monobasic processing at Lys13 followed by carboxypeptidase trimming. We found that K13A mutation did not block PSST[1-10] production. Since the prosomatostatin sequence R8-Q9-F10-L11 \ qualifies as a potential SKI-1 substrate, using a vaccinia virus expression system along with HPLC and radioimmunoassays, we observed that overexpression of recombinant SKI-1 in COS-1 and HEK-293 cells significantly increased the production of PSST[1-10]. Additionally, in CHO cells lacking SKI-1, there was a significant reduction in PSST[1-10] production which could be increased upon SKI-1 stimulation. Mutagenesis studies showed that efficient processing of PSST to PSST[1-10] required the RXRXXL motif. However, this NH2-terminal cleavage was not a prerequisite for the formation of SST-14 and SST-28.